Immunovant Income Statement (2018-2026) | IMVT

Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter)
21.36M29.76M31.99M28.43M37.74M42.25M51.84M50.58M47.96M48.34M66.06M75.47M97.27M94.52M93.65M101.20M114.25M98.92M142.29M142.63M
Selling, General & Administrative (Quarter)
16.29M11.52M15.24M11.95M11.88M11.78M12.42M15.40M13.84M13.21M14.82M18.81M18.47M19.78M20.17M26.02M17.51M15.44M17.27M17.69M
Other Operating Expenses (Quarter)
10.00M12.50M
Operating Expenses (Quarter)
37.65M41.27M47.23M40.38M49.61M64.03M64.26M78.48M61.80M61.55M80.88M94.28M115.74M114.30M113.83M127.22M131.76M114.36M159.55M160.32M
Operating Income (Quarter)
EBIT (Quarter)
-35.42M-39.75M-46.96M-40.01M-45.35M51.73M31.57M60.33M332.87M377.91M-71.72M129.69M126.04M67.93M112.93M-45.89M-77.82M8.12M161.30M31.38M
Non-operating items
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)
-0.08M-0.11M0.04M0.35M0.79M-1.76M0.36M0.46M0.02M1.09M-2.59M0.03M0.63M-1.26M1.07M1.19M0.25M-0.05M0.80M0.00M
Non Operating Income (Quarter)
4.07M3.57M8.93M8.38M7.18M6.07M4.59M6.89M6.34M5.60M5.33M8.06M7.09M
Net income details
EBT (Quarter)
-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M-153.22M
Tax Provisions (Quarter)
-0.03M-0.01M0.35M0.26M0.39M-0.99M-0.01M0.45M-0.11M0.23M0.08M0.08M0.15M0.58M0.91M0.59M1.55M-2.86M
Profit After Tax (Quarter)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Income from Continuing Operations (Quarter)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M-153.22M
Consolidated Net Income (Quarter)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M-153.22M
Income towards Parent Company (Quarter)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M-153.22M
Net Income towards Common Stockholders (Quarter)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.84M-153.22M
Additional items
EPS (Basic) (Quarter)
-0.35-0.36-0.43-0.35-0.41-0.49-0.48-0.57-0.45-0.36-0.55-0.60-0.74-0.76-0.70-0.71-0.73-0.61-0.81-0.75
EPS (Diluted) (Quarter)
-0.35-0.36-0.43-0.35-0.41-0.49-0.48-0.57-0.45-0.36-0.55-0.60-0.74-0.76-0.70-0.71-0.73-0.61-0.81-0.75
Shares Outstanding (Quarter)
109.08M115.03M109.68M116.56M116.57M128.57M123.08M130.50M131.16M144.52M138.10M146.09M146.47M146.92M151.57M170.87M173.64M181.51M182.42M205.55M
Shares Outstanding (Diluted) (Quarter)
109.08M115.03M109.68M116.56M116.57M128.57M123.08M130.50M131.16M144.52M138.10M146.09M146.47M146.92M151.57M170.87M173.64M181.51M182.42M205.55M
Shares Outstanding (Entity) (Quarter)
115.00M115.11M116.48M116.52M116.61M129.26M130.33M130.57M131.44M145.09M145.58M146.20M146.57M147.20M170.11M171.07M174.53M203.32M203.94M206.26M
EBITDA (Quarter)
-35.42M-39.75M-46.96M-40.01M-45.35M51.73M31.57M60.33M332.87M377.91M-71.72M129.69M126.04M67.93M112.93M-45.89M-77.82M8.12M161.30M31.38M
Interest Expenses (Quarter)
2.32M1.64M0.22M0.01M2.32M114.57M91.99M134.27M391.08M429.43M3.36M216.77M235.08M178.90M218.80M73.81M48.09M117.20M312.00M184.60M
Tax Rate (Quarter)
0.08%0.03%-0.88%-0.55%-0.62%1.64%0.01%-0.78%0.21%-0.31%-0.09%-0.07%-0.14%-0.55%-0.76%-0.47%-1.42%1.90%